Skip to main content
Alpa Laboratories Limited logo

Alpa Laboratories Limited — Investor Relations & Filings

Ticker · ALPA ISIN · INE385I01010 LEI · 335800O2RIWENG8KPR59 BSE.NS Manufacturing
Open in API
Filings indexed 321 across all filing types
Latest filing 2026-05-29 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS ALPA

About Alpa Laboratories Limited

https://alpalabs.in/

Alpa Laboratories Limited specializes in the development and manufacture of a broad range of pharmaceutical formulations for human and veterinary applications. The company's core capabilities include the production of small volume parenterals, such as liquid and dry powder injections, alongside solid orals like tablets and capsules. Its portfolio further extends to topical preparations including ointments, creams, gels, and ophthalmic/otic drops. Utilizing WHO-GMP certified manufacturing units, the organization provides extensive contract manufacturing and research services to prominent global healthcare brands. The company serves diverse therapeutic segments, including anti-infectives, analgesics, and nutritional supplements, maintaining a robust presence in both domestic and international markets through a commitment to stringent quality standards and technical excellence.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Interim / Quarterly Report Classification · 75% confidence The document is an Outcome of Board Meeting under SEBI Listing Regulations providing the Audited Standalone & Consolidated Financial Results (including full P&L statements and notes) for the quarter and year ended March 31, 2026. It contains comprehensive financial tables and actual financial data, not just highlights or a brief announcement. It is not a full Annual Report (10-K), but rather a periodic financial report with detailed figures, matching our “Interim / Quarterly Report” (IR) definition. FY 2026
2026-05-29 English
Results for the quarter and year ended March,2026
Interim / Quarterly Report Classification · 85% confidence The document is a statutory announcement under SEBI Listing Regulations of the Board’s approval of the audited financial results (quarter and full year ended 31 March 2026), including detailed standalone and consolidated financial statements in Annexure A, auditor’s report (Annexure B), and related disclosures. It contains actual comprehensive financial data (P&L statements, notes, EPS) rather than a mere publication notice or high-level highlights. This fits the definition of an Interim/Quarterly Report (IR) because it is a standalone report of periodical financial results filed to the exchanges, even though it includes year-end numbers. FY 2026
2026-05-29 English
Alpa Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Audited Standalone & Consolidated ....
Regulatory Filings Classification · 85% confidence The document is an intimation of a Board Meeting under SEBI Listing Obligations (Regulation 29/30), notifying the stock exchange of a future board meeting to consider and approve financial results. It does not contain the actual financial results or auditor’s report, nor is it announcing a management change or publishing a report itself. Therefore, it is a general regulatory announcement and best fits the Regulatory Filings category (RNS).
2026-05-12 English
Appointment
Board/Management Information Classification · 95% confidence The document is a listing regulation compliance notice under SEBI (Listing Obligations and Disclosure Requirements) Regulation 30 regarding the appointment of the Company Secretary and Compliance Officer. It announces a change in senior management. This matches the Board/Management Information category.
2026-04-11 English
Price movement
Regulatory Filings Classification · 100% confidence The document text is extremely short (85 characters) and contains no substantive content, only placeholders and an omitted picture. There is no financial data, no report content, no announcements, or any textual information to classify as a specific report type. Given the lack of content, the document cannot be classified as a report or announcement. According to the rules, such minimal or empty content defaults to Regulatory Filings (RNS) as a fallback category.
2026-04-09 English
Trading Window
Regulatory Filings Classification · 85% confidence The document is a formal intimation to stock exchanges regarding the closure of the trading window under SEBI insider trading regulations. It does not contain financial statements or votes, nor is it a notice of dividend, share issuance, or management change. It is a compliance announcement fitting under general regulatory filings.
2026-03-20 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.